Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus

Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus

Abstract Background The lipid-lowering and positive cardiovascular effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors was shown in several studies, hence, they are more widely used in the lipid-lowering management of individuals with high cardiovascular risk. As real-world da...

Full description

Bibliographic Details
Main Authors: Laurenz T. Fischer, Daniel A. Hochfellner, Lisa Knoll, Tina Pöttler, Julia K. Mader, Felix Aberer
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Cardiovascular Diabetology
Subjects:
PCSK9 inhibitor therapy
Lipid lowering therapy
Real world data
Online Access:https://doi.org/10.1186/s12933-021-01283-w

Similar Items

Similar Items